Literature DB >> 31273560

Hereditary diffuse gastric cancer: cancer risk and the personal cost of preventive surgery.

P Kaurah1,2, A Talhouk3, A MacMillan4, I Lewis4, K Chelcun-Schreiber5, S S Yoon6, D Huntsman7,8.   

Abstract

Germline CDH1 mutation carriers are at risk for early-onset diffuse gastric cancer (DGC) and female carriers have an additional risk of lobular breast cancer. The reported literature GC risk of 70% has led to the recommendation for germline mutation carriers to undergo prophylactic total gastrectomy (PTG). The objective of this research was to examine post-surgical clinical outcomes and to identify which of the domains/symptoms from the European Organisation for Research and Treatment of Cancer QOL Questionnaire (EORTC QLQ-C30) were determinants of overall quality of life (QOL) in individuals undergoing PTG. Participants were recruited through multiple sources. Postsurgical clinical outcomes were obtained from hospital records. Participants completed validated questionnaires measuring generic and condition specific QOL (PROMIS, EORTC and SF 36v.II) at a single point in time. The mean QOL in this cohort was 70.6 (SD = 25.6), which is better than reference values from the general populations in USA and Canada Role and social function plus the symptoms anxiety, pain, taste, dyspnea and diarrhea were significant predictor variables for QOL (p < 0.05). Although this study reveals good overall QOL for individuals after PTG, attention should be given to managing symptoms as part of long term care to further enhance QOL. The function/symptom scores were associated with worse overall health and global health status and thus may mark a real need for more attentive post-surgical care.

Entities:  

Keywords:  Clinical outcomes; Diffuse gastric cancer; Predictor variables; Quality of life; Total prophylactic gastrectomy

Mesh:

Year:  2019        PMID: 31273560      PMCID: PMC8164729          DOI: 10.1007/s10689-019-00133-9

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  38 in total

Review 1.  Germline E-cadherin gene mutations: is prophylactic total gastrectomy indicated?

Authors:  Y S Chun; N M Lindor; T C Smyrk; B T Petersen; L J Burgart; P J Guilford; J H Donohue
Journal:  Cancer       Date:  2001-07-01       Impact factor: 6.860

2.  Prophylactic total gastrectomy in hereditary diffuse gastric cancer: identification of two novel CDH1 gene mutations-a clinical observational study.

Authors:  Linda Bardram; Thomas V O Hansen; Anne-Marie Gerdes; Susanne Timshel; Lennart Friis-Hansen; Birgitte Federspiel
Journal:  Fam Cancer       Date:  2014-06       Impact factor: 2.375

3.  Assessment of quality of life after gastrectomy using EORTC QLQ-C30 and STO22.

Authors:  Daisuke Kobayashi; Yasuhiro Kodera; Michitaka Fujiwara; Masahiko Koike; Goro Nakayama; Akimasa Nakao
Journal:  World J Surg       Date:  2011-02       Impact factor: 3.352

4.  Prophylactic total gastrectomy for individuals with germline CDH1 mutation.

Authors:  Prakash K Pandalai; Greg Y Lauwers; Daniel C Chung; Devanshi Patel; Sam S Yoon
Journal:  Surgery       Date:  2010-08-17       Impact factor: 3.982

5.  Changes of quality of life after gastric cancer surgery.

Authors:  Horyon Kong; Oh Kyung Kwon; Wansik Yu
Journal:  J Gastric Cancer       Date:  2012-09-30       Impact factor: 3.720

6.  The association of depression and anxiety with health-related quality of life in cancer patients with depression and/or pain.

Authors:  Linda F Brown; Kurt Kroenke; Dale E Theobald; Jingwei Wu; Wanzhu Tu
Journal:  Psychooncology       Date:  2010-07       Impact factor: 3.894

7.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.

Authors:  N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes
Journal:  J Natl Cancer Inst       Date:  1993-03-03       Impact factor: 13.506

Review 8.  Pathological features of total gastrectomy specimens from asymptomatic hereditary diffuse gastric cancer patients and implications for clinical management.

Authors:  João P Rocha; Irene Gullo; Xiaogang Wen; Vítor Devezas; Manuela Baptista; Carla Oliveira; Fátima Carneiro
Journal:  Histopathology       Date:  2018-10-09       Impact factor: 5.087

9.  CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer.

Authors:  Jeffrey A Norton; Christine M Ham; Jacques Van Dam; R Brooke Jeffrey; Teri A Longacre; David G Huntsman; Nicki Chun; Allison W Kurian; James M Ford
Journal:  Ann Surg       Date:  2007-06       Impact factor: 12.969

10.  The quality of life after a total gastrectomy with extended lymphadenectomy and omega type oesophagojejunostomy for gastric adenocarcinoma without distant metastases.

Authors:  Gintare Jakstaite; Narimantas Evaldas Samalavicius; Giedre Smailyte; Raimundas Lunevicius
Journal:  BMC Surg       Date:  2012-06-27       Impact factor: 2.102

View more
  10 in total

Review 1.  Hereditary diffuse gastric cancer: updated clinical practice guidelines.

Authors:  Vanessa R Blair; Maybelle McLeod; Fátima Carneiro; Daniel G Coit; Johanna L D'Addario; Jolanda M van Dieren; Kirsty L Harris; Nicoline Hoogerbrugge; Carla Oliveira; Rachel S van der Post; Julie Arnold; Patrick R Benusiglio; Tanya M Bisseling; Alex Boussioutas; Annemieke Cats; Amanda Charlton; Karen E Chelcun Schreiber; Jeremy L Davis; Massimiliano di Pietro; Rebecca C Fitzgerald; James M Ford; Kimberley Gamet; Irene Gullo; Richard H Hardwick; David G Huntsman; Pardeep Kaurah; Sonia S Kupfer; Andrew Latchford; Paul F Mansfield; Takeshi Nakajima; Susan Parry; Jeremy Rossaak; Haruhiko Sugimura; Magali Svrcek; Marc Tischkowitz; Toshikazu Ushijima; Hidetaka Yamada; Han-Kwang Yang; Adrian Claydon; Joana Figueiredo; Karyn Paringatai; Raquel Seruca; Nicola Bougen-Zhukov; Tom Brew; Simone Busija; Patricia Carneiro; Lynn DeGregorio; Helen Fisher; Erin Gardner; Tanis D Godwin; Katharine N Holm; Bostjan Humar; Caroline J Lintott; Elizabeth C Monroe; Mark D Muller; Enrique Norero; Yasmin Nouri; Joana Paredes; João M Sanches; Emily Schulpen; Ana S Ribeiro; Andrew Sporle; James Whitworth; Liying Zhang; Anthony E Reeve; Parry Guilford
Journal:  Lancet Oncol       Date:  2020-08       Impact factor: 41.316

Review 2.  Quality of Life After Curative Resection for Gastric Cancer: Survey Metrics and Implications of Surgical Technique.

Authors:  Yinin Hu; Victor M Zaydfudim
Journal:  J Surg Res       Date:  2020-03-07       Impact factor: 2.192

3.  Diagnosis of MALT Lymphoma from Surveillance Endoscopy of a Patient with a CDH1 Gene Germline Mutation.

Authors:  Cláudia Pinto; Ana Luísa Cunha; Ângelo Rodrigues; Renata Dias; Catarina Brandão; Mário Dinis-Ribeiro
Journal:  GE Port J Gastroenterol       Date:  2021-03-11

Review 4.  CDH1 (E-Cadherin) Mutation and Gastric Cancer: Genetics, Molecular Mechanisms and Guidelines for Management.

Authors:  Santosh Shenoy
Journal:  Cancer Manag Res       Date:  2019-12-13       Impact factor: 3.989

5.  Gastric Signet-Ring-Cell Adenocarcinoma with Delayed Retroperitoneal Metastasis and Fibrosis.

Authors:  Matthew G K Benesch; Alexander Mathieson
Journal:  Case Rep Oncol       Date:  2022-02-14

6.  Four cases of gastric adenocarcinoma and proximal polyposis of the stomach treated by robotic total gastrectomy.

Authors:  Yosuke Iwakawa; Kozo Yoshikawa; Koichi Okamoto; Tetsuji Takayama; Takuya Tokunaga; Toshihiro Nakao; Masaaki Nishi; Chie Takasu; Hideya Kashihara; Yuma Wada; Toshiaki Yoshimoto; Shoko Yamashita; Mitsuo Shimada
Journal:  Surg Case Rep       Date:  2022-04-18

7.  CDH1 Gene Mutation Hereditary Diffuse Gastric Cancer Outcomes: Analysis of a Large Cohort, Systematic Review of Endoscopic Surveillance, and Secondary Cancer Risk Postulation.

Authors:  Matthew G K Benesch; Stuart R Bursey; Andrew C O'Connell; Morag G Ryan; Carrie L Howard; Cecily C Stockley; Alexander Mathieson
Journal:  Cancers (Basel)       Date:  2021-05-26       Impact factor: 6.639

8.  Barriers and facilitators to CDH1 carriers contemplating or undergoing prophylactic total gastrectomy.

Authors:  Kaitlin M McGarragle; Tae L Hart; Carol Swallow; Savtaj Brar; Anand Govindarajan; Zane Cohen; Melyssa Aronson
Journal:  Fam Cancer       Date:  2020-08-05       Impact factor: 2.375

9.  Epidemiology of Signet Ring Cell Adenocarcinomas.

Authors:  Matthew G K Benesch; Alexander Mathieson
Journal:  Cancers (Basel)       Date:  2020-06-11       Impact factor: 6.639

10.  Comparative Analysis of Clavien-Dindo Grade and Risk Factors of Complications after Dual-Port Laparoscopic Distal Gastrectomy and Hand-Assisted Laparoscopic Gastrectomy.

Authors:  Haihao Jin; Jianshan Geng
Journal:  J Oncol       Date:  2021-07-09       Impact factor: 4.375

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.